Proteon Therapeutics Announces Third Quarter 2017 Financial Results
November 07, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
September 05, 2017 07:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2017 Financial Results
August 07, 2017 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
August 02, 2017 19:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces $22.0 Million Private Placement
June 22, 2017 09:31 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
June 15, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces First Quarter 2017 Financial Results
May 10, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
May 10, 2017 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
May 02, 2017 16:40 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
May 01, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...